Join CILcare and CBSET at the STP 38th Annual Symposium on June 22-27, 2019 in Raleigh, North Carolina. Meet our experts to learn about our cutting-edge GLP preclinical services for the evaluation of hearing disorders and regenerative therapies.
Suchi RAGHUNATHAN, Ph.D, CILcare’s Scientist and Cyrille SAGE, Ph.D, CILcare’s R&D Project Manager, Senior Scientist will be presenting a poster: “Ototoxicity Related to Cisplatin: Does Gender Matter?“.
Cisplatin is a first-line treatment of several cancers. Adverse effects include nephrotoxicity, neurotoxicity, and ototoxicity with no preventative treatment for the latter. Cisplatin treatment often results in a bilateral elevation of hearing threshold resulting in irreversible hearing loss.
John Keating, DVM, DACVP, CBSET’s Director of Pathology, is speaking on: “Medical Device Safety Assessment: The Frontiers of Safety Assessment Pathology” on Sunday June 23, from 11:30 AM–12:00 Noon during the session on Hernia Mesh Implants.
Join CILcare and CBSET at booth #300. Our experts will be pleased to discuss how the leaders in GLP ototoxicity studies can help you advance your novel therapies through early efficacy trials and GLP safety assessment.
About STP 38th Annual Symposium
The 38th Annual Symposium of the Society of Toxicologic Pathology will take place in Raleigh, North Carolina on June 22-27, 2019. The theme for the 2019 Annual Symposium is “Environmental Toxicologic Pathology and One Health” and promises to be another dynamic meeting with excellent scientific sessions, continuing education courses, and many networking opportunities.
